title: Beta-blockers are associated with reduced risk of myocardial infarction after cocaine use.
abstract: OBJECTIVE
  Beta-blocker use is associated with coronary artery spasm after cocaine administration but also decreases mortality in patients with myocardial infarction or systolic dysfunction. We conduct a retrospective cohort study to analyze the safety of beta-blockers in patients with positive urine toxicology results for cocaine.
  
  
  METHODS
  The cohort consisted of 363 consecutive telemetry and ICU patients who were admitted to a municipal hospital and had positive urine toxicology results for cocaine during a 5-year period (307 patients). Fifteen patients with uncertain history of beta-blocker use before admission were excluded. The primary outcome measure was myocardial infarction; secondary outcome measure was inhospital mortality. Logistic regression analysis using generalized estimating equations models and propensity scores compared outcomes.
  
  
  RESULTS
  Beta-blockers were given in 60 of 348 admissions. The incidence of myocardial infarction after administration of beta-blocker was significantly lower than without treatment (6.1% versus 26.0%; difference in proportion 19.9%; 95% confidence interval [CI] 10.3% to 30.0%). One of 14 deaths occurred in patients who received beta-blockade (incidence 1.7% versus 4.5% without beta-blockade; difference in proportion 2.8%; 95% CI -1.2% to 6.7%). Multivariate analysis showed that use of beta-blockers significantly reduced the risk of myocardial infarction (odds ratio 0.06; 95% CI 0.01 to 0.61).
  
  
  CONCLUSIONS
  In our cohort, administration of beta-blockers was associated with reduction in incidence of myocardial infarction after cocaine use. The benefit of beta-blockers on myocardial function may offset the risk of coronary artery spasm.
authors.affiliation: Department of Medicine, Jacobi Medical Center, Bronx, NY 10461, USA.
authors.forename: Philip B
authors.initials: PB
authors.lastname: Dattilo
authors.forename: Susan M
authors.initials: SM
authors.lastname: Hailpern
authors.forename: Kerrie
authors.initials: K
authors.lastname: Fearon
authors.forename: Davendra
authors.initials: D
authors.lastname: Sohal
authors.forename: Charles
authors.initials: C
authors.lastname: Nordin
mesh_terms: D000319:Adrenergic beta-Antagonists / Q000494:pharmacology / Q000627:therapeutic use*; D000328:Adult; D019970:Cocaine-Related Disorders / Q000150:complications*; D000075202:Contraindications; D005260:Female; D017052:Hospital Mortality; D006801:Humans; D016015:Logistic Models; D008297:Male; D008875:Middle Aged; D009203:Myocardial Infarction / Q000139:chemically induced* / Q000453:epidemiology / Q000401:mortality / Q000517:prevention & control; D012189:Retrospective Studies; D015983:Selection Bias; D019210:Troponin I / Q000097:blood
chemical_list: D000319:Adrenergic beta-Antagonists; D019210:Troponin I